Cite
HARVARD Citation
Liu, L. et al. (n.d.). 74P The safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients (pts) with locally recurrent or metastatic triple-negative breast cancer (TNBC): A multi-cohort, phase II trial. Immuno-oncology technology. p. . [Online].